Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paliperidone palmitate versus oral paliperidone or risperidone in symptomatic schizophrenia
ACTRN12618001113246Phase 4Completed
- Sponsor
- University of Turin
- Start
- Feb 2017
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of paliperidone palmitate, paliperidone and risperidone in schizophrenia (3 arms), sponsored by University of Turin. Primary endpoints: Change in Treatment Satisfaction Questionnaire for Medication total score, Change in Subjective Well-being under Neuroleptics scale score and 1 more. Started Feb 2017; status: completed.
02
Drugs
paliperidone palmitatepaliperidonerisperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on ACTRN12618001113246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001113246.